Serum IL‐24 combined with CA125 as screening and prognostic biomarkers for NSCLC
Cell Biology International · 2024
DOI: 10.1002/cbin.12173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology International, 2024. Verfasst von Kai Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Biomarkers, Tumor, CA-125 Antigen, Interleukins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Science and Technology Research Project, Medical Science and Technology Joint Construction Project of Henan Province, PhD research startup foundation of the Third Affiliated Hospital of Zhengzhou University.
Abstract (Originalsprache)
Noninvasive and effective methods for early screening of non‐small cell lung cancer (NSCLC) still need to be developed. At present, a reasonable conclusion is that a combination of tumor markers is a superior predictor of screening. Cytokines, as important regulators of cancer development, have great potential for the screening and prognosis of NSCLC. This study screened novel biomarkers related to the early screening and prognosis of NSCLC. In the present study, the biological significance and immunoregulation of interleukin‐24 (IL‐24) were analyzed based on The Cancer Genome Atlas data. Next, 150 serum samples from initially treated patients with NSCLC and 70 controls were collected, and we obtained pathological sections from 60 patients with NSCLC. The ELISA and immunohistochemistry results showed the differential expression of IL‐24 and carbohydrate antigen 125 (CA125). The results show that IL‐24 is an important tumor suppressor in NSCLC that helps to improve the poor prognosis of these patients. A significantly negative correlation between IL‐24 and CA125 levels was also found. Notably, serum IL‐24 levels were significantly negatively correlated with the TNM stage of patients with NSCLC, consistent with an important role for tumor suppressors in NSCLC. The receiver operating characteristic curve analysis showed that a combination of IL‐24 and CA125 was an effective panel for discriminating patients with NSCLC from HD, and individuals with other lung diseases. Serum IL‐24 and CA125 levels were identified as independent prognostic markers for NSCLC. The IL‐24 and CA125 panel exhibited good performance in the screening of NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
- Zhengzhou Key Laboratory for In Vitro Diagnosis of Hypertensive Disorders of Pregnancy, Zhengzhou, Henan, China.
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Förderung
- Henan Provincial Science and Technology Research Project
- Medical Science and Technology Joint Construction Project of Henan Province
- PhD research startup foundation of the Third Affiliated Hospital of Zhengzhou University
Zitieren
APA
Zhang, K., Qu, J., Deng, S., & Yuan, E. (2024). Serum IL‐24 combined with CA125 as screening and prognostic biomarkers for NSCLC. Cell Biology International. https://doi.org/10.1002/cbin.12173
Vancouver
Zhang K, Qu J, Deng S, Yuan E. Serum IL‐24 combined with CA125 as screening and prognostic biomarkers for NSCLC. Cell Biology International. 2024. doi:10.1002/cbin.12173
BibTeX
@article{Zhang2024,
author = {Zhang, Kai and Qu, Jiao and Deng, Shu and Yuan, Enwu},
title = {Serum IL‐24 combined with CA125 as screening and prognostic biomarkers for NSCLC},
journal = {Cell Biology International},
year = {2024},
doi = {10.1002/cbin.12173}
}
EUVIMED